ATE349521T1 - Mit cd40 und traf interagierende proteine - Google Patents

Mit cd40 und traf interagierende proteine

Info

Publication number
ATE349521T1
ATE349521T1 AT99922165T AT99922165T ATE349521T1 AT E349521 T1 ATE349521 T1 AT E349521T1 AT 99922165 T AT99922165 T AT 99922165T AT 99922165 T AT99922165 T AT 99922165T AT E349521 T1 ATE349521 T1 AT E349521T1
Authority
AT
Austria
Prior art keywords
traf
met
proteins interacting
kappab
proteins
Prior art date
Application number
AT99922165T
Other languages
English (en)
Inventor
Stefan Maria Christiaan Pype
Jacques Emile Fernand Remacle
Danny Francois Eve Huylebroeck
Original Assignee
Vlaams Interuniv Inst Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlaams Interuniv Inst Biotech filed Critical Vlaams Interuniv Inst Biotech
Application granted granted Critical
Publication of ATE349521T1 publication Critical patent/ATE349521T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT99922165T 1998-04-29 1999-04-28 Mit cd40 und traf interagierende proteine ATE349521T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98201392 1998-04-29

Publications (1)

Publication Number Publication Date
ATE349521T1 true ATE349521T1 (de) 2007-01-15

Family

ID=8233659

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99922165T ATE349521T1 (de) 1998-04-29 1999-04-28 Mit cd40 und traf interagierende proteine

Country Status (8)

Country Link
US (2) US6812203B1 (de)
EP (1) EP1073739B1 (de)
JP (1) JP2002512796A (de)
AT (1) ATE349521T1 (de)
AU (1) AU752597B2 (de)
CA (1) CA2327504A1 (de)
DE (1) DE69934580T2 (de)
WO (1) WO1999055859A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69934580T2 (de) 1998-04-29 2007-10-04 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Mit cd40 und traf interagierende proteine
WO2002024194A2 (en) * 2000-09-19 2002-03-28 Novimmune S.A. Use of statins (hmg-coa reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
WO2004074815A2 (en) * 2003-02-14 2004-09-02 Beth Israel Deaconess Medical Center, Inc. Predicting graft rejection
WO2012054584A2 (en) 2010-10-19 2012-04-26 The Regents Of The University Of Colorado, A Body Corporate Peptides for modulating t-cell activity and uses thereof
US20190263888A1 (en) 2010-10-19 2019-08-29 Op-T Llc Therapeutic peptides and methods for treating autoimmune related disease
TWI502199B (zh) * 2013-05-23 2015-10-01 Univ Nat Central 腫瘤壞死因子受體相關因子７作爲紅斑性狼瘡的生物標記物之用途、偵測人體患有紅斑性狼瘡的方法以及偵測人體患有紅斑性狼瘡的套組
US11793854B2 (en) * 2019-03-21 2023-10-24 Op-T Llc Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction
US12048734B2 (en) 2020-04-17 2024-07-30 Op-T Llc Bioactive peptides and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6265556B1 (en) * 1994-12-02 2001-07-24 The Burnham Institute Nucleic acid encoding CD40 associated proteins
US5705625A (en) * 1994-12-15 1998-01-06 The Johns Hopkins University School Of Medicine Nucleic Acid Encoding novel protein tyrosine kinase
US5577124A (en) 1995-03-09 1996-11-19 Arithmetica, Inc. Multi-purpose high speed cryptographically secure sequence generator based on zeta-one-way functions
US6348567B1 (en) * 1995-12-06 2002-02-19 Cv Molecular Therapeutics Inc. Peptides and their use to ameliorate cell death
DE19610262A1 (de) 1996-03-15 1997-09-18 Bayer Ag Verfahren zur Herstellung Kohlenwasserstoff-getriebener Polyurethan-Hartschaumstoffe
AU2593997A (en) * 1996-03-21 1997-10-10 Trustees Of Columbia University In The City Of New York, The Craf1 (traf-3) isoforms and uses thereof
WO1998034946A1 (en) * 1997-02-12 1998-08-13 Massachusetts Institute Of Technology Daxx, a novel fas-binding protein that activates jnk and apoptosis
JPH1175856A (ja) * 1997-09-17 1999-03-23 Takashi Tsuruo トポイソメラーゼ結合タンパク質
AU2010699A (en) * 1997-12-24 1999-07-19 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for theiruse
US6379951B1 (en) * 1997-12-24 2002-04-30 Corixa Corporation Compounds for immunotherapy of breast cancer and methods for their use
DE69934580T2 (de) 1998-04-29 2007-10-04 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Mit cd40 und traf interagierende proteine
CA2311201A1 (en) * 1999-08-05 2001-02-05 Genset S.A. Ests and encoded human proteins

Also Published As

Publication number Publication date
EP1073739B1 (de) 2006-12-27
DE69934580T2 (de) 2007-10-04
US6812203B1 (en) 2004-11-02
AU752597B2 (en) 2002-09-26
EP1073739A2 (de) 2001-02-07
JP2002512796A (ja) 2002-05-08
US20050101769A1 (en) 2005-05-12
US7098322B2 (en) 2006-08-29
DE69934580D1 (de) 2007-02-08
CA2327504A1 (en) 1999-11-04
WO1999055859A2 (en) 1999-11-04
WO1999055859A3 (en) 2000-02-17
AU3931099A (en) 1999-11-16

Similar Documents

Publication Publication Date Title
AU2002305450A1 (en) Proteomimetic compounds and methods
EA200200755A1 (ru) Опосредованная рецептором nogo блокада роста аксонов
ATE467425T1 (de) Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben
EP1137658A4 (de) VERFAHREN ZUR MODULATION VON TUMOR NECROSIS FAKTOR -g(a)-INDUZIERTER EXPRESSION VON ZELLADHÄSIONSMOLEKÜLEN
DE60028970D1 (de) An her2 bindende peptidverbindungen
ATE230394T1 (de) Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
DE69738581D1 (de) Menschliche dnase i hyperaktive varianten
EP1248794A4 (de) Antisens-modulierung der smad7 expression
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
DE69535673D1 (de) Mittel zur induktion von apoptosis und zur therapieanwendung
ATE433461T1 (de) Rana pipiens proteine und deren verwendung in der behandlung von tumoren
DE69934580D1 (de) Mit cd40 und traf interagierende proteine
DE69821793D1 (de) Neuronale verwendungen des bmp-11
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
ATE316084T1 (de) Substituierte diazepan
ATE287722T1 (de) Mittel zur behandlung maligner erkrankungen unter verwendung des proteins yb-1
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
DE69912743D1 (de) Behandlung von follikulären lymphomen unter verwendung von inhibitoren des lymphotoxin (lt)-aktivierungsweges
DE60037978D1 (de) Interferon ähnliche moleküle, und deren verwendungen
DE69916488D1 (de) Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren
TR200200278T2 (tr) Kalsilitik bileşimler
DE69309790D1 (de) Cyclopentanperhydrophenanthren-17-beta-(3-Furyl)-3-Derivate und pharmazeutische Präparate davon, zur Behandlung von Kardiovaskulär-Erkrankungen
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
ATE298244T1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen
DE60229924D1 (de) Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties